

ASX RELEASE

10 January 2025

Release of Shares from Voluntary Escrow

Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) confirms in accordance with ASX Listing Rule 3.10A that 781,250 ordinary shares issued on 19 July 2024 as a fee for services of a corporate advisor will be released from voluntary escrow on 19 January 2025.

This ASX announcement is authorised for release by the Company Secretary.

- End -

Investor Contact:

Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com

Media Contact:

HACK Director, Haley Chartres
haley@hck.digital
+61 423 139 163

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on [Twitter](https://twitter.com/ampliatx) (@ampliatx) and [LinkedIn](https://www.linkedin.com/company/ampliatx).